TWiV 817: COVID-19 clinical update #84 with Dr. Daniel Griffin
Oct 16, 2021•46 min•Ep. 817
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In COVID-19 clinical update #84, Dr. Griffin discusses childrens' antibody response to vaccination, phase 3 results of Novavax vaccine, heterologous vaccination, antithrombotic therapy, EUA for molnupiravir, phase 3 results of AZD7442, serum ferritin levels and outcomes, heparin therapy, and WHO strategy for global vaccination.
Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free): iTunes, Google Podcasts, RSS, emailBecome a patron of TWiV!
Links for this episode- Antibody profiles after mRNA vaccination in children (bioRxiv)
- Novavax vaccine phase 3 results (medRxiv)
- Heterologous vaccine boosters (medRxiv)
- Antithrombotic therapy outcomes (JAMA)
- Molnupiravir EUA submitted (Merck)
- AZD7442 phase 3 results (AstraZeneca)
- Serum ferritin levels and disease outcome (JAMA)
- Heparin efficacy (JAMA)
- WHO strategy to vaccinate world (WHO)
- Letters read on TWiV 817
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
For the best experience, listen in Metacast app for iOS or Android